Keywords: Novartis, FDA advisory panel, Gilenia, Fingolimod, Multiple sclerosis, Merck KGaA, Cladribine
FDA Advisory Committee unanimously backs Gilenia, putting Novartis ahead in race for oral MS drug
Article | 11 June 2010
Despite some reservations about the safety profile of Swiss drug major Novartis’ drug by US Food and Drug Administration reviewers ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
